In breast cancer, AKR1B10 is upregulated in ductal carcinoma in situ, infiltrating carcinoma and recurrent cancer, and correlated with tumor size, lymph node metastasis, and worse survival, being a negative prognostic factor 31. Here, AKR1B10 is linked to neoplasm.